Therapeutic interfering particles against HIV: molecular parasites reducing viremia.
作者信息
Gruell Henning, Odidika Stanley, Schommers Philipp
机构信息
Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
出版信息
Signal Transduct Target Ther. 2024 Oct 14;9(1):287. doi: 10.1038/s41392-024-02001-0.
Abstract
摘要
相似文献
1
Therapeutic interfering particles against HIV: molecular parasites reducing viremia.抗HIV治疗性干扰颗粒：降低病毒血症的分子寄生物
Signal Transduct Target Ther. 2024 Oct 14;9(1):287. doi: 10.1038/s41392-024-02001-0.
2
[Preventing rebound viremia after ending ART. Long-term control].
MMW Fortschr Med. 2014 Jun 12;156 Suppl 1:10.
3
Viremia control despite escape from a rapid and potent autologous neutralizing antibody response after therapy cessation in an HIV-1-infected individual.在一名HIV-1感染个体停止治疗后，尽管其逃脱了快速且强效的自身中和抗体反应，但仍实现了病毒血症控制。
J Immunol. 2003 Apr 1;170(7):3906-14. doi: 10.4049/jimmunol.170.7.3906.
4
Enfuvirtide antiviral activity despite rebound viremia and resistance mutations: fitness tampering or a case of persistent braking on entering?恩夫韦肽尽管出现病毒血症反弹和耐药突变仍具有抗病毒活性：适应性干扰还是进入时持续制动的案例？
J Infect Dis. 2007 Feb 1;195(3):318-21. doi: 10.1086/510539. Epub 2006 Dec 21.
5
Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels.HIV-1 耐药性检测在低病毒载量患者中的可靠性和临床相关性。
Clin Infect Dis. 2014 Apr;58(8):1156-64. doi: 10.1093/cid/ciu020. Epub 2014 Jan 14.
6
Development of Kaposi sarcoma despite sustained suppression of HIV plasma viremia.尽管HIV血浆病毒血症持续受到抑制，但仍发生了卡波西肉瘤。
J Acquir Immune Defic Syndr. 2000 Apr 1;23(4):361. doi: 10.1097/00126334-200004010-00017.
7
Continued production of drug-sensitive human immunodeficiency virus type 1 in children on combination antiretroviral therapy who have undetectable viral loads.接受联合抗逆转录病毒治疗且病毒载量检测不到的儿童中持续产生1型药物敏感型人类免疫缺陷病毒。
J Virol. 2004 Jan;78(2):968-79. doi: 10.1128/jvi.78.2.968-979.2004.
8
Minor viral population with drug-resistant mutation and risk of persistent low-level viremia or 'blips' in HIV-1 subtype C.
AIDS. 2014 Nov 13;28(17):2635-6. doi: 10.1097/QAD.0000000000000463.
9
High viremia and low level of transmitted drug resistance in anti-retroviral therapy-naïve perinatally-infected children and adolescents with HIV-1 subtype C infection.高病毒载量和低传播耐药水平在抗逆转录病毒治疗初治的母婴传播感染 HIV-1 型 C 亚型的儿童和青少年中。
BMC Infect Dis. 2012 Nov 22;12:317. doi: 10.1186/1471-2334-12-317.
10
Residual Viremia in Treated HIV+ Individuals.接受治疗的HIV阳性个体中的残余病毒血症
PLoS Comput Biol. 2016 Jan 6;12(1):e1004677. doi: 10.1371/journal.pcbi.1004677. eCollection 2016 Jan.
本文引用的文献
1
Engineered deletions of HIV replicate conditionally to reduce disease in nonhuman primates.工程化缺失的 HIV 能在条件下复制，从而减少非人类灵长类动物的疾病。
Science. 2024 Aug 9;385(6709):eadn5866. doi: 10.1126/science.adn5866.
2
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women.双年度利纳卡帕韦或每日 F/TAF 用于预防 cisgender 女性中的 HIV。
N Engl J Med. 2024 Oct 3;391(13):1179-1192. doi: 10.1056/NEJMoa2407001. Epub 2024 Jul 24.
3
The case for transmissible antivirals to control population-wide infectious disease.用于控制人群传染病的可传播抗病毒药物。
Trends Biotechnol. 2014 Aug;32(8):400-5. doi: 10.1016/j.tibtech.2014.06.006. Epub 2014 Jul 10.
4
Influenza virus protecting RNA: an effective prophylactic and therapeutic antiviral.流感病毒保护RNA：一种有效的预防性和治疗性抗病毒药物。
J Virol. 2008 Sep;82(17):8570-8. doi: 10.1128/JVI.00743-08. Epub 2008 Jun 25.
5
Defective viral particles and viral disease processes.有缺陷的病毒颗粒与病毒疾病过程。
Nature. 1970 Apr 25;226(5243):325-7. doi: 10.1038/226325a0.
Zotero 插件